WeVote
Log In

Bill

Bill

S 4013

Permits clinical laboratories to provide certain patients discounts without affecting NJ FamilyCare reimbursement rates or violating NJ Familycare rebate prohibitions.

2024-2025 Regular Session Introduced by Patrick Diegnan and 1 co-sponsor

New Jersey legislation exempts clinical laboratory discount programs from affecting Medicaid reimbursement rates and rebate rules to improve patient affordability.

Introduced in the Senate, Referred to Senate Health, Human Services and Senior Citizens Committee
#healthfac #healthinsur
0
WeVote Research Nonpartisan
Bill Summary · S 4013

Legislative bill overview

S 4013 allows clinical laboratories in New Jersey to offer discounts to certain patients without triggering reductions in NJ FamilyCare (the state's Medicaid program) reimbursement rates or violating rebate prohibitions. The bill creates a carve-out permitting discount programs to operate independently from state payment rate determinations and rebate regulations that normally apply to laboratory services.

Why is this important

Out-of-pocket laboratory costs can be significant barriers to healthcare access for uninsured and underinsured patients. This bill aims to expand patient affordability options while protecting state budgets from reimbursement pressures, potentially increasing lab test utilization among cost-sensitive populations without increasing government spending.

Potential points of contention

  • Definition ambiguity: The bill doesn't specify which patients qualify for discounts or how laboratories should determine eligibility, creating potential for inconsistent application or abuse
  • Budget impact clarity: Unclear whether allowing discounts might indirectly pressure FamilyCare reimbursement rates downward or affect cost-sharing arrangements with other payers
  • Rebate prohibition mechanics: The carve-out from rebate rules needs clarification on how it interacts with existing federal and state anti-kickback statutes and pricing transparency requirements
  • Competitive fairness: May create unequal playing field if large laboratory chains can absorb discounts while smaller providers cannot

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.